Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor

Crit Care. 2008;12(1):R17. doi: 10.1186/cc6791. Epub 2008 Feb 18.

Abstract

Introduction: In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the present study, we tried to characterize in vitro monocyte baseline cytokine production and responsiveness to lipopolysaccharide exposure.

Methods: Twenty-two consecutive patients with cancer were prospectively enrolled into a prospective observational study in an intensive care unit. All patients developed septic ARDS and were divided into two groups: neutropenic patients (n = 12) and non-neutropenic patients (n = 10). All of the neutropenic patients received granulocyte colony-stimulating factor whereas no patient in the non-neutropenic group received granulocyte colony-stimulating factor. We compared monocytes from neutropenic patients with septic ARDS with monocytes from non-neutropenic patients and healthy control individuals (n = 10). Peripheral blood monocytes were cultured, and cytokine levels (TNFalpha, IL-1beta, IL-6, IL-10, and IL-1 receptor antagonist) were assayed with and without lipopolysaccharide stimulation.

Results: TNFalpha, IL-6, IL-10 and IL-1 receptor antagonist levels in unstimulated monocytes were lower in neutropenic patients compared with non-neutropenic patients. Values obtained in the healthy individuals were low as expected, comparable with neutropenic patients. In lipopolysaccharide-stimulated monocytes, both inflammatory and anti-inflammatory cytokine production were significantly lower in neutropenic patients compared with non-neutropenic patients and control individuals.

Conclusion: Consistent with previous results concerning alveolar macrophage deactivation, we observed a systemic deactivation of monocytes in septic neutropenic ARDS. This deactivation participates in the overall immunodeficiency and could be linked to sepsis, chemotherapy and/or the use of granulocyte colony-stimulating factor.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Cytokines / biosynthesis*
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Lipopolysaccharides
  • Macrophage Activation
  • Male
  • Middle Aged
  • Monocytes / metabolism*
  • Neoplasms / complications
  • Neutropenia / complications
  • Neutropenia / drug therapy
  • Neutropenia / metabolism*
  • Neutropenia / mortality
  • Respiratory Distress Syndrome / complications
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / metabolism

Substances

  • Cytokines
  • Lipopolysaccharides
  • Granulocyte Colony-Stimulating Factor